Sep 30 |
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
|
Sep 27 |
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
|
Sep 9 |
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
|
Aug 23 |
Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings
|
Aug 22 |
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
|
Aug 20 |
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
|
Aug 14 |
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylmâ„¢
|
Aug 9 |
Oppenheimer sees Aquestive benefitting from FDA okay of rival drug
|
Aug 8 |
Aquestive Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
Aug 7 |
Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript
|